Armando Fraire to Biomarkers, Tumor
This is a "connection" page, showing publications Armando Fraire has written about Biomarkers, Tumor.
Connection Strength
0.381
-
Cai YC, Roggli V, Mark E, Cagle PT, Fraire AE. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med. 2004 Jan; 128(1):68-70.
Score: 0.173
-
Cornejo KM, Shi M, Akalin A, Uy K, Cagle PT, Fraire AE. Pulmonary papillary adenoma: a case report and review of the literature. J Bronchology Interv Pulmonol. 2013 Jan; 20(1):52-7.
Score: 0.081
-
Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007 Dec; 20(12):1263-8.
Score: 0.056
-
Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007 Feb; 20(2):242-7.
Score: 0.053
-
Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011 Jun; 35(6):878-82.
Score: 0.018